MSI-78 Magainin Pharmaceuticals

IDrugs

Volumn 1, Issue 5, 1998, Pages 605-609

  Islam, Khalid ^a   Hawser, Stephen P ^a  

^a SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33748141634     PISSN: 13697056     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (73)

1. In vivo antimicrocial activity of magainin topical cream against mixed skin flora. Leyden JJ, McGinley KJ, Rowinski CA, Wever AE, Jacob LS ICAAC 1993 33rd New Orleans Abs 474
2. Shareholder report. Magainin Pharmaceuticals Inc PRESS RELEASE 1994 July 29
3. Magainin Pharmaceuticals. ANNUAL REPORT 1993
4. Magainin Pharmaceuticals Inc. FORM 10-K 1993
5. Comparison of topical agents Magainin MSI-78 and mupirocin, potential for resistance development in Staphylococcus aureus. MacDonald D, Jones L, Messler C ICAAC 1993 33rd New Orleans 309
6. In vivo efficacy of a magainin compound MSI-78 in a swine model of wound infection. MacDonald DL, Weber A, Patterson H, Jacob L ICAAC 1992 32nd Anaheim 197
7. The effect of topical magainin MSI-78 on Staphylococcus aureus proliferation in wounds. Marshall DA, Mertz PM, Cazzaniga AL, Eaglstein WH, Weber A, Berkowitz B, Jacob LS CLIN RES 1991 39 2 566A
8. Antimicrobial peptides from tongues. SCRIP 1995 2013 31
9. Magainin: Wounded, but still carrying its shield IN VIVO 1995 13 2 45
10. Margainin Pharmaceuticals Inc. ANNUAL REPORT 1994
11. Antimicrobial and anticancer agents from vertebrates: Searching frogs, sharks, and man. Zasloff M ACS 1995 209th Anaheim MEDI 231
12. Magainin achieves positive phase III data. PRESS RELEASE 1995 July 03
13. MSI-78/Ofloxacin (Floxin). Magainin Pharmaceuticals Inc CLIN TRIALS MONITOR 1995 4 8 P12
14. Magainin Pharmaceuticals Inc. FORM 10-K 1994 December 31
15. Magainin Pharmaceuticals Inc. ANNUAL REPORT 1994
16. Magainin Pharmaceuticals Inc announces initiation of second pivotal phase III trial of MSI-78. Magainin Pharmaceuticals Inc PRESS RELEASE 1995 August 31
17. MSI-78 meets interim clinical trial objective. Magainin Pharmaceuticals Inc PRESS RELEASE 1995 July 27
18. Magainin's MSI-78 in second Phase III trial. SCRIP 1995 2062 22
19. Magainin Pharmaceuticals Inc. UBS SECURITIES LIFE SCI ANNU CONF 1995 Oct 17-18th New York A97-A98
20. Magainin Pharmaceuticals Inc: BugBusters. Hambrecht & Quist Inc, Wilson T, Thibeault K ANALYST REPORT 1993 March 16
21. Potential therapeutic applications of magainins and other antimicrobial agents of animal origin. Jacob L, Zasloff M CIBA FOUND SYMP 1994 186 197-223
22. Hambrecht & Quist Health Care Conference-San Francisco January 1996. HAMBRECHT & QUIST 1996 January 7-10
23. Magainin Pharmaceuticals Inc. ANNUAL REPORT 1995 December
24. Magainin announces successful MSI-7B phase III trial results. Magainin Pharmaceuticals Inc PRESS RELEASE 1996 September 25
25. Houghten Pharmaceuticals receives stock in exchange for royalty interest in Magainin's lead compound. Houghten Pharmaceuticals Inc PRESS RELEASE 1996 September 26
26. US clinical trials update. SCRIP 1996 2170 27
27. Magainin Pharmaceuticals Inc (OTC: MAGN). UBS SECURITIES LIFE SCI ANNU CONF 1996 March 19-20 London A62
28. Phase III data positive for Magainin's Cytolex. BIOWORLD WEEK 1996 4 40 4
29. UBS Biotech monthly. ANALYST REPORT 1996 February 26
30. Using host defenses to fight infectious diseases. Kelly KJ NATURE BIOTECHNOL 1996 14 5 587-590
31. Magainin's squalamine in clinic by '97? SCRIP 1996 2175 19
32. Clinical trial update: September 1996. BIOWORLD FINANCIAL WATCH 1996 4 44 7-10
33. Magainin announces Cytolex collaboration with SmithKline Beecham in North America. Magainin Pharmaceuticals Inc PRESS RELEASE 1997 February 13
34. Cytolex royalties buy-out boosts Magainin net loss SCRIP 1997 2211 7
35. Smithkline to pay Magainin $32M for Cytolex. BIOWORLD WEEK 1997 5 7 4
36. Maiginin announces successful results of second pivotal trial for Cytolex (MSI-78) Magainin Pharmaceuticals Inc PRESS RELEASE 1997 March 18
37. SmithKline Beecham to market magainin Cytolex antibiotic cream. FDC REPORTS PINK SHEET 1997 59 7 T&G-12
38. Magainin set to file NDA for Cytolex. BIOWORLD WEEK 1997 5 12 3
39. Cytolex NDA filing by end of year. SCRIP 1997 2219/20 19
40. Magainin/SB agreement for Cytolex. SCRIP 1997 2208 7
41. Magainin Pharmaceuticals announces first quarter financial results. Magainin Pharmaceuticals Inc PRESS RELEASE 1997 April 29
42. Magainin receives $5 million milestone payment from SmithKline Beecham. Magainin Pharmaceuticals Inc PRESS RELEASE 1997 June 02
43. Magainin's $5 million milestone for Cytolex. SCRIP 1997 2239 12
44. Magainin Pharmaceuticals Inc. FORM 10-K 1996 December 31
45. Magainin Pharmaceuticals announces second quarter financial results. Magainin Pharmaceuticals Inc PRESS RELEASE 1997 July 24
46. Magainin Pharmaceuticals buys out MSI-78 royalty stream. Magainin Pharmaceuticals Inc PRESS RELEASE 1996 September 26
47. Magainin ready to file NDA after second of Cytolex. Seachrist L BIOWORLD TODAY 1997 8 53 1-5
48. SmithKline to pay Magainin $32M for antibiotic cream. Craig C BIOWORLD TODAY 1997 8 31 1-4
49. Phase III data positive for Magainin's anti-infective drug. Craig C BIOWORLD TODAY 1996 7 189 1-5
50. Magainin presents phase III clinical trial results for novel antibiotic, Cytolex, at ICAAC meeting; also to evaluate wound healing studies. Magainin Pharmaceuticals Inc PRESS RELEASE 1997 September 29
51. Current approaches to overcome bacterial resistance. Setti EL, Quattrocchio L, Micetich RG DRUGS FUTURE 1997 22 3 271-284
52. Magainin Pharmaceuticals announces third quarter financial results. Magainin Pharmaceuticals Inc PRESS RELEASE 1997 October 20
53. On the antibacterial activity of normal and reversed magainin 2 analogs against Helicobacter pylori. Iwahori A, Hirota Y, Sampe R, Miyano S, takahashi N, Sasatsu M, Kondo I, Numao N BIOL PHARM BULL 1997 20 7 805-808
54. Analyst Report 1997. ANALYST REPORT 1997
55. Magainin to enter into joint venture with Ambalal Sarabhai Enterprises Limited in India. Magainin Pharmaceuticals Inc PRESS RELEASE 1998 January 12
56. Microbial eradication and clinical resolution of infected diabetic foot ulcers treated with topical MSI-78 vs oral ofloxacin. Lipsky BA, Litka PA, Zasloff M, Nelson K ICAAC 1997 Toronto LM-57
57. Magainin Cytolex being considered for wound-healing indication FDC REPORTS PINK SHEET 1997 59 42 T&G-10-T&G-11
58. Magainin/Ambalal Sarabhai form joint venture in India. SCRIP 1998 2302 12
59. Magainin seeks $27M. BIOWORLD WEEK 1997 5 43 3
60. Magainin Pharmaceuticals. ANALYST REPORT 1998 21 January
61. The therapeutic potential of cationic peptides. Hancock REW EXP OPIN INVEST DRUGS 1998 7 2 167-174
62. Analyst report-antibiotic therapeutic review. Colletta A, Brewer M, Beadle D, Brindle S ANALYST REPORT 1998 February
63. Magainin announces 1997 financial results. Magainin Pharmaceuticals Inc PRESS RELEASE 1998 February 13
64. 1997 Annual Report - Magainin. ANNUAL REPORT 1997
65. Antibacterial activity of the two alkylamines integrated into an indane scaffold: Mimicry of a complimentary unit on Magainin 2. Numao N BIOL PHARM BULL 1997 20 800-804
66. Structure-activity studies on magainins and other host defense proteins Maloy WL, Prasad U BIOPOLYMERS 1995 37 105-122
67. In vitro activity of MSI-78, an analog of the frog skin antibiotic, magainin, versus ofloxocin againt aerobic clinical isolates from hospitals throughout the United States. Macdonald DL ICAAC 1997 Abs F45
68. Peptide antibiotics. Hancock REW LANCET 1997 349 418-422
69. In vitro antimicrobial activity of MSI-78, a magainin analog. Fuchs PC, Barry AL, Brown SD ANTIMICROB AGENTS CHEMOTHER 1998 42 5 1213-1216
70. Pexiganan acetate. Topical antimicrobial. Graul A, Leeson P DRUGS FUTURE 1998 23 3 271-273
71. Killing of Fusobacterium nucleatum, Porphyromonas gingivalis and Prevotella intermedia by protegrins. Miyasaki KT, Iofel R, Oren A, Huynh T, Lehrer RI J PERIODONTAL RES 1998 33 2 91-98
72. Magainin's topical antibiotic enters Phase II/III. SCRIP 1993 1816 30
73. Magainin peptide disappoints in impetigo. SCRIP 1994 1915 27